Anteris Technologies Global (AVR) Non-Current Debt (2025 - 2026)
Anteris Technologies Global's (AVR) quarterly Non-Current Debt came in at $47000.0 in Q2 2026, up 56.67% year-over-year from $30000.0 in Q2 2025, and up 161.11% quarter-over-quarter from $18000.0 in Q1 2026.
Powered by 
Analysis
Anteris Technologies Global (AVR) Non-Current Debt (2025 - 2026) Analysis & Trends
Anteris Technologies Global (AVR) has reported Non-Current Debt for 2 consecutive years, with $47000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Debt rose 56.67% year-over-year to $47000.0 in Q2 2026; TTM through Jun 2026 was $47000.0, a 56.67% increase from a year earlier, with the FY2025 full-year figure at $22000.0, changed N/A from the prior year.
- Non-Current Debt was $47000.0 for Q2 2026 at Anteris Technologies Global, up from $18000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $47000.0 in Q2 2026 and troughed at $18000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 25.62 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 14.19 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 10.92 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 598.70 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -1.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Anteris Technologies Global | 806.46 Mn | 806.46 Mn | 776,000.00 | 47,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |